Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Sarepta CEO Chris Garabedian resigns

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

UPDATED: Sarepta's embattled CEO steps down as DMD drug heads to the FDA

Chris Garabedian, the bullish, controversial CEO of Sarepta Therapeutics, has resigned from his post, leaving the company just as it prepares to file its Duchenne muscular dystrophy treatment for FDA approval.

Lilly execs take $3M hit to 2014 bonuses, but the pay freeze thaws for 2015

Suffering from generic competition and patent losses, Eli Lilly & Co. froze salaries and cut bonuses last year--from the top management ranks on down. But the decreases in incentive pay didn't make a huge dent in those executive pay packages.

Former Teva CEO Levin returns to biopharma as chairman of upstart Ovid Therapeutics

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Baxter pays execs more than $8.5M to stick it out through pharma spinoff

Baxter chief Robert Parkinson--who makes a perennial appearance on the list of the top-paid helmsman in biopharma--is in prime position to return this year, despite a drop in his overall compensation. But as for his colleagues gearing up to help biopharma spinoff Baxalta break free, they're in line for some pay bumps--assuming they stick around after the split.

The $600 million man: Gilead CEO's stock gains push compensation way past estimates

Year by year, drugmakers disclose the compensation they hand out to top executives. But the year-by-year numbers don't tell the full story. As Reuters notes, CEOs have reaped payoffs much bigger than proxy filings estimate, as long-term share awards meet big stock gains.

UPDATED: GlaxoSmithKline tags 180 sales-and-admin jobs for cutting in NC

Last year, GlaxoSmithKline announced plans to slim down its Research Triangle Park, NC-based operations, chopping 900 jobs. Now, it's telling state officials that almost 200 workers are heading for the door.

Regeneron chief nabs $42M, but he'll have to pay his own club fees this year

Regeneron chief Len Schleifer has topped the ranks of biopharma's highest-paid skippers for the past couple of years now, and though his salary may be rising still, being CEO doesn't quite come with all the perks it used to.

UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ

Times have been tough for Daiichi Sankyo, and they're about to get tougher for some of the Japanese company's U.S. staffers. The drugmaker is cutting its headquarters staff by 16% on Monday, with more layoffs expected in mid-April.

AbbVie CEO pads $16M paycheck with $500K in jet travel

For the first couple of years after AbbVie's debut as an independent pharma company, its CEO, Richard Gonzalez, didn't quite follow in Abbott Laboratories CEO Miles White's footsteps compensation-wise, collecting a mere $8 million in 2012 pay. But for 2014, Gonzalez's total compensation amounted to $22 million, according to AbbVie's proxy statement.